Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?

Diabetic retinopathy (DR) is among the leading causes of new onset blindness in adults. Effective treatment may delay the onset and progression of this disease provided it is diagnosed early. At present retinopathy can only be diagnosed via formal examination of the eye by a trained specialist, whic...

Full description

Bibliographic Details
Main Authors: Priyia ePusparajah, Learn-Han eLee, Khalid eAbdul Kadir
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-06-01
Series:Frontiers in Physiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00200/full
_version_ 1818951650829664256
author Priyia ePusparajah
Learn-Han eLee
Learn-Han eLee
Khalid eAbdul Kadir
author_facet Priyia ePusparajah
Learn-Han eLee
Learn-Han eLee
Khalid eAbdul Kadir
author_sort Priyia ePusparajah
collection DOAJ
description Diabetic retinopathy (DR) is among the leading causes of new onset blindness in adults. Effective treatment may delay the onset and progression of this disease provided it is diagnosed early. At present retinopathy can only be diagnosed via formal examination of the eye by a trained specialist, which limits the population that can be effectively screened. An easily accessible, reliable screening biomarker of diabetic retinopathy would be of tremendous benefit in detecting the population in need of further assessment and treatment. This review highlights specific biomarkers that show promise as screening markers to detect early diabetic retinopathy or even to detect patients at increased risk of DR at the time of diagnosis of diabetes. The pathobiology of DR is complex and multifactorial giving rise to a wide array of potential biomarkers. This review provides an overview of these pathways and looks at older markers such as advanced glycation end products(AGEs), inflammatory markers, vascular endothelial growth factor (VEGF) as well as other newer proteins with a role in the pathogenesis of DR including neuroprotective factors such as brain derived neurotrophic factor (BDNF) and Pigment Epithelium Derived Factor (PEDF); SA100A12, pentraxin 3, brain natriuretic peptide, apelin 3 and chemerin as well as various metabolites such as lipoprotein A, folate and homocysteine. We also consider the possible role of proteins identified through proteomics work whose levels are altered in the sera of patients with DR as screening markers though their role in pathophysiology remains to be characterized. The role of microRNA as a promising new screening marker is also discussed.
first_indexed 2024-12-20T09:37:52Z
format Article
id doaj.art-8cfffc59c14546aaa17199736f605e2b
institution Directory Open Access Journal
issn 1664-042X
language English
last_indexed 2024-12-20T09:37:52Z
publishDate 2016-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Physiology
spelling doaj.art-8cfffc59c14546aaa17199736f605e2b2022-12-21T19:44:56ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2016-06-01710.3389/fphys.2016.00200202236Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?Priyia ePusparajah0Learn-Han eLee1Learn-Han eLee2Khalid eAbdul Kadir3Monash University MalaysiaMonash University MalaysiaUniversity of PhayaoMonash University MalaysiaDiabetic retinopathy (DR) is among the leading causes of new onset blindness in adults. Effective treatment may delay the onset and progression of this disease provided it is diagnosed early. At present retinopathy can only be diagnosed via formal examination of the eye by a trained specialist, which limits the population that can be effectively screened. An easily accessible, reliable screening biomarker of diabetic retinopathy would be of tremendous benefit in detecting the population in need of further assessment and treatment. This review highlights specific biomarkers that show promise as screening markers to detect early diabetic retinopathy or even to detect patients at increased risk of DR at the time of diagnosis of diabetes. The pathobiology of DR is complex and multifactorial giving rise to a wide array of potential biomarkers. This review provides an overview of these pathways and looks at older markers such as advanced glycation end products(AGEs), inflammatory markers, vascular endothelial growth factor (VEGF) as well as other newer proteins with a role in the pathogenesis of DR including neuroprotective factors such as brain derived neurotrophic factor (BDNF) and Pigment Epithelium Derived Factor (PEDF); SA100A12, pentraxin 3, brain natriuretic peptide, apelin 3 and chemerin as well as various metabolites such as lipoprotein A, folate and homocysteine. We also consider the possible role of proteins identified through proteomics work whose levels are altered in the sera of patients with DR as screening markers though their role in pathophysiology remains to be characterized. The role of microRNA as a promising new screening marker is also discussed.http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00200/fullDiabetic Retinopathyscreeningbiomarkerspersonalized medicineearly stage retinopathy
spellingShingle Priyia ePusparajah
Learn-Han eLee
Learn-Han eLee
Khalid eAbdul Kadir
Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
Frontiers in Physiology
Diabetic Retinopathy
screening
biomarkers
personalized medicine
early stage retinopathy
title Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
title_full Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
title_fullStr Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
title_full_unstemmed Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
title_short Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?
title_sort molecular markers of diabetic retinopathy potential screening tool of the future
topic Diabetic Retinopathy
screening
biomarkers
personalized medicine
early stage retinopathy
url http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00200/full
work_keys_str_mv AT priyiaepusparajah molecularmarkersofdiabeticretinopathypotentialscreeningtoolofthefuture
AT learnhanelee molecularmarkersofdiabeticretinopathypotentialscreeningtoolofthefuture
AT learnhanelee molecularmarkersofdiabeticretinopathypotentialscreeningtoolofthefuture
AT khalideabdulkadir molecularmarkersofdiabeticretinopathypotentialscreeningtoolofthefuture